Short- and Long-term Biologic Variability of Galectin-3 and Other Cardiac Biomarkers in Patients with Stable Heart Failure and Healthy Adults.

Autor:	Schindler EI; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology., Szymanski JJ; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology., Hock KG; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology., Geltman EM; Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Scott MG; Division of Laboratory and Genomic Medicine, Department of Pathology and Immunology, mscott@path.wustl.edu.
Jazyk:	angličtina
Zdroj:	Clinical chemistry [Clin Chem] 2016 Feb; Vol. 62 (2), pp. 360-6. Date of Electronic Publication: 2015 Nov 06.
DOI:	10.1373/clinchem.2015.246553
Abstrakt:	Background: Galectin-3 (Gal-3) has been suggested as a prognostic biomarker in heart failure (HF) patients that may better reflect disease progression than traditional markers, including B-type natriuretic peptide (BNP) and cardiac troponins. To fully establish the utility of any biomarker in HF, its biologic variability must be characterized. Methods: To assess biologic variability, 59 patients were prospectively recruited, including 23 male and 16 female patients with stable HF and 10 male and 10 female healthy individuals. Gal-3, BNP, and high-sensitivity cardiac troponin I (hs-cTnI) were assayed at 5 time points within a 3-week period to assess short-term biologic variability. Long-term (3-month) biologic variability was assessed with samples collected at enrollment and after 4, 8, and 12 weeks. Results: Among healthy individuals, mean short-term biologic variability, expressed as intraindividual CV (CVI), was 4.5% for Gal-3, 29.0% for BNP, and 14.5% for hs-cTnI; long-term biologic variability was 5.5% for Gal-3, 34.7% for BNP, and 14.7% for hs-cTnI. In stable HF patients, mean short-term biologic variability was 7.1% for Gal-3, 22.5% for BNP, and 8.5% for hs-cTnI, and mean long-term biologic variability was 7.7% for Gal-3, 27.6% for BNP, and 9.6% for hs-cTnI. Conclusions: The finding that Gal-3 has minimal intraindividual biological variability adds to its potential as a useful biomarker in HF patients. (© 2015 American Association for Clinical Chemistry.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu